A Translational Rodent Assay of Affective Biases in Depression and Antidepressant Therapy

[1]  E. Robinson,et al.  Investigating the psychopharmacology of cognitive affective bias in rats using an affective tone discrimination task , 2013, Psychopharmacology.

[2]  E. Robinson,et al.  Investigating the roles of different monoamine transmitters and impulse control using the 5-choice serial reaction time task , 2013, Journal of psychopharmacology.

[3]  M. Thase,et al.  Are We Getting Closer to Valid Translational Models for Major Depression? , 2012, Science.

[4]  C. Harmer,et al.  Experimental and Clinical Psychopharmacology Acute Antidepressant Drug Administration and Autobiographical Memory Recall : A Functional Magnetic Resonance Imaging Study , 2012 .

[5]  M. Papp.  Models of Affective Illness: Chronic Mild Stress in the Rat , 2012, Current protocols in pharmacology.

[6]  M. Munafo,et al.  Amphetamine as a social drug: effects of d-amphetamine on social processing and behavior , 2012, Psychopharmacology.

[7]  K. Wingenfeld,et al.  HPA Axis Alterations in Mental Disorders: Impact on Memory and its Relevance for Therapeutic Interventions , 2011, CNS neuroscience & therapeutics.

[8]  G. Dawson,et al.  Agomelatine facilitates positive versus negative affective processing in healthy volunteer models , 2011, Journal of psychopharmacology.

[9]  P. Cowen,et al.  A cognitive neuropsychological model of antidepressant drug action , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[10]  Ian B Hickie,et al.  Novel melatonin-based therapies: potential advances in the treatment of major depression , 2011, The Lancet.

[11]  T. Robbins,et al.  Translating cognition from animals to humans. , 2011, Biochemical pharmacology.

[12]  M. Mendl,et al.  An integrative and functional framework for the study of animal emotion and mood , 2010, Proceedings of the Royal Society B: Biological Sciences.

[13]  S. Hyman,et al.  Animal models of neuropsychiatric disorders , 2010, Nature Neuroscience.

[14]  P. Cowen,et al.  NK1 receptor antagonism and emotional processing in healthy volunteers , 2010, Journal of psychopharmacology.

[15]  I. Gotlib,et al.  Cognition and depression: current status and future directions. , 2010, Annual review of clinical psychology.

[16]  P. Cowen,et al.  Effect of acute antidepressant administration on negative affective bias in depressed patients. , 2009, The American journal of psychiatry.

[17]  P. Cowen,et al.  Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action , 2009, British Journal of Psychiatry.

[18]  F. Zitman,et al.  Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. , 2009, Archives of general psychiatry.

[19]  Rupert Lanzenberger,et al.  Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram , 2009, International clinical psychopharmacology.

[20]  P. Cowen,et al.  Early effects of mirtazapine on emotional processing , 2009, Psychopharmacology.

[21]  P. Cowen,et al.  Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers , 2009, Psychopharmacology.

[22]  C. Nemeroff,et al.  The link between childhood trauma and depression: Insights from HPA axis studies in humans , 2008, Psychoneuroendocrinology.

[23]  N. Lodge,et al.  Behavioral and Pharmacological Validation of the Gerbil Forced-Swim Test: Effects of Neurokinin-1 Receptor Antagonists , 2008, Neuropsychopharmacology.

[24]  J. Rumsfeld,et al.  The hope and fear of rimonabant. , 2008, JAMA.

[25]  K. Berridge,et al.  Affective neuroscience of pleasure: reward in humans and animals , 2008, Psychopharmacology.

[26]  C. Lowry,et al.  Pharmacology of the beta-carboline FG-7,142, a partial inverse agonist at the benzodiazepine allosteric site of the GABA A receptor: neurochemical, neurophysiological, and behavioral effects. , 2007, CNS drug reviews.

[27]  Vikram Patel,et al.  Depression, chronic diseases, and decrements in health: results from the World Health Surveys , 2007, The Lancet.

[28]  K. Ressler,et al.  Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic , 2007, Nature Neuroscience.

[29]  P. Cowen,et al.  Direct effects of diazepam on emotional processing in healthy volunteers , 2007, Psychopharmacology.

[30]  P. Cowen,et al.  A single dose of citalopram increases fear recognition in healthy subjects , 2007, Journal of psychopharmacology.

[31]  D. Slattery,et al.  Animal models of mood disorders: recent developments , 2007, Current opinion in psychiatry.

[32]  P. Fossati,et al.  Episodic autobiographical memory in depression: Specificity, autonoetic consciousness, and self-perspective , 2006, Consciousness and Cognition.

[33]  Jarmo Hietala,et al.  Lack of Efficacy of the Substance P (Neurokinin1 Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder , 2006, Biological Psychiatry.

[34]  Kally C. O'Reilly,et al.  Chronic Administration of 13-Cis-Retinoic Acid Increases Depression-Related Behavior in Mice , 2006, Neuropsychopharmacology.

[35]  J. Leppänen.  Emotional information processing in mood disorders: a review of behavioral and neuroimaging findings , 2006, Current opinion in psychiatry.

[36]  S. Ferguson,et al.  Chronic oral treatment with 13-cis-retinoic acid (isotretinoin) or all-trans-retinoic acid does not alter depression-like behaviors in rats. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[37]  John F. Cryan,et al.  Model organisms: The ascent of mouse: advances in modelling human depression and anxiety , 2005, Nature Reviews Drug Discovery.

[38]  A. Young,et al.  A differential pattern of neural response toward sad versus happy facial expressions in major depressive disorder , 2005, Biological Psychiatry.

[39]  John Suckling,et al.  Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. , 2004, Archives of general psychiatry.

[40]  P. Cowen,et al.  Increased Positive versus Negative Affective Perception and Memory in Healthy Volunteers following Selective Serotonin and Norepinephrine Reuptake Inhibition , 2022 .

[41]  M. Bourin,et al.  Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. , 2004, Journal of psychiatry & neuroscience : JPN.

[42]  M. Mendl,et al.  Animal behaviour: Cognitive bias and affective state , 2004, Nature.

[43]  P. Cowen,et al.  Toward a neuropsychological theory of antidepressant drug action: increase in positive emotional bias after potentiation of norepinephrine activity. , 2003, The American journal of psychiatry.

[44]  K. Perry,et al.  The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions , 2003, British journal of pharmacology.

[45]  L. Stinus,et al.  In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs , 2002, Behavioural Brain Research.

[46]  David M. Diamond,et al.  The stressed hippocampus, synaptic plasticity and lost memories , 2002, Nature Reviews Neuroscience.

[47]  J. Kelly,et al.  Reboxetine attenuates forced swim test-induced behavioural and neurochemical alterations in the rat , 1999, European Neuropsychopharmacology.

[48]  W. Mcbride,et al.  Place conditioning with alcohol in alcohol-preferring and -nonpreferring rats , 1996, Pharmacology Biochemistry and Behavior.

[49]  S. Verney,et al.  Unconscious mood-congruent memory bias in depression. , 1996, Journal of abnormal psychology.

[50]  R. Rodgers,et al.  Ethopharmacological analysis of the effects of putative ‘anxiogenic’ agents in the mouse elevated plus-maze , 1995, Pharmacology Biochemistry and Behavior.

[51]  M. Bardo,et al.  Conditioned place preference using opiate and stimulant drugs: A meta-analysis , 1995, Neuroscience & Biobehavioral Reviews.

[52]  J. Rabe-Jabłońska,et al.  [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders]. , 1993, Psychiatria polska.

[53]  H. Kraemer,et al.  Facial emotion discrimination: II. Behavioral findings in depression , 1992, Psychiatry Research.

[54]  J. Hyttel,et al.  Prolonged treatment with the specific 5-HT-uptake inhibitor citalopram: effect on dopaminergic and serotonergic functions. , 1984, Polish journal of pharmacology and pharmacy.

[55]  R. Porsolt,et al.  Depression: a new animal model sensitive to antidepressant treatments , 1977, Nature.

[56]  Larry H. Strasburger,et al.  Depression—Clinical, Experimental, and Theoretical Aspects , 1968 .

[57]  Samuel R. Friedman,et al.  Depression: Clinical, Experimental, and Theoretical Aspects , 1968 .

[58]  R. Elliott,et al.  Cognitive Mechanisms of Treatment in Depression , 2012, Neuropsychopharmacology.

[59]  J. Bremner,et al.  Retinoic acid and affective disorders: the evidence for an association. , 2012, The Journal of clinical psychiatry.

[60]  E. Robinson.  Blockade of noradrenaline re-uptake sites improves accuracy and impulse control in rats performing a five-choice serial reaction time tasks , 2011, Psychopharmacology.

[61]  Rebecca Elliott,et al.  Affective Cognition and its Disruption in Mood Disorders , 2011, Neuropsychopharmacology.

[62]  I. Lucki,et al.  Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test , 2005, Psychopharmacology.

[63]  C. MacLeod,et al.  Cognitive vulnerability to emotional disorders. , 2005, Annual review of clinical psychology.

[64]  D. Wong,et al.  Fluoxetine and its two enantiomers as selective serotonin uptake inhibitors. , 1990, Acta pharmaceutica Nordica.